CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2585-A |

# Specialty Guideline Management Palynziq

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Palynziq | pegvaliase-pqpz |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy

### FDA-approved Indications1

Palynziq is indicated to reduce blood phenylalanine (Phe) concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management.

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review: blood phenylalanine concentration greater than 600 micromol/L or genetic testing results supporting diagnosis.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or phenylketonuria (PKU).

## Coverage Criteria

### Phenylketonuria (PKU)1

Authorization of 6 months may be granted for treatment of phenylketonuria (PKU) when all of the following criteria are met:

* Member is 18 years of age or older.
* Baseline blood phenylalanine concentration, prior to initiation of the requested medication, is greater than 600 micromol/L.

Note: If Palynziq is initiated in a member currently receiving Kuvan for phenylketonuria (PKU), then Kuvan will be discontinued after an appropriate period of overlap.

## Continuation of Therapy

### Phenylketonuria (PKU)1

Authorization of 12 months may be granted for members who have achieved a clinical response as evidenced by achieving a blood phenylalanine concentration of less than or equal to 600 micromol/L.

Authorization of 6 months may be granted for members who have not achieved an adequate clinical response to treatment with the requested medication of blood phenylalanine concentration less than or equal to 600 micromol/L and the member meets one of the following requirements:

* Member has not been titrated to the maximum allowed dose of 60 mg once daily.
* Member has received less than 16 weeks of continuous treatment at the maximum allowed dose of 60 mg once daily.

Note: Palynziq should not be used concomitantly with Kuvan for phenylketonuria (PKU).

## References

1. Palynziq [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; November 2020.